Headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.9695286191801 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern’s analysis:
Several research analysts recently issued reports on the stock. BidaskClub cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th. Citigroup reduced their target price on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a report on Thursday, August 9th. Maxim Group cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Keryx Biopharmaceuticals in a report on Thursday, August 9th. Finally, ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $6.25.
KERX traded up $0.10 on Thursday, reaching $3.14. The stock had a trading volume of 13,197 shares, compared to its average volume of 1,215,313. Keryx Biopharmaceuticals has a 12-month low of $2.93 and a 12-month high of $8.07. The company has a debt-to-equity ratio of -3.16, a quick ratio of 1.40 and a current ratio of 2.28. The stock has a market capitalization of $395.11 million, a price-to-earnings ratio of -3.57 and a beta of 2.59.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). equities research analysts forecast that Keryx Biopharmaceuticals will post -0.58 earnings per share for the current year.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Recommended Story: What is the NASDAQ?
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.